CRP and fibromyalgia: From another perspective, our finding showed that retention rate and effectiveness during the 24-month follow-up were comparable between secukinumab and TNFi with a hazard ratio (HR) of 0.99 (95% CI: 0.41 to 2.36) after adjusting for age, sex, ASDAS-CRP at baseline, and fibromyalgia.